Hui-Yi Lin

Title: Hui-Yi Lin: Inventor in Prostate Cancer Research.

Introduction

Hui-Yi Lin is an inventor based in Tampa, Florida, and is associated with H. Lee Moffitt Cancer Center and Research Institute, Inc. His patent work addresses the assessment of prostate cancer recurrence risk.

Latest Patents

Lin is credited with 1 patent: “Determining prostate cancer recurrence using polymorphisms in angiogenesis-related genes.” The disclosed method genotypes a patient’s nucleic acid sample for single nucleotide polymorphism alleles in angiogenesis-related genes, compares those alleles with control frequencies to create a genetic signature, and analyzes that signature to generate a risk score. The score can indicate the likelihood of recurrence after radical prostatectomy. In particular, a high score for a patient with positive surgical margins may indicate an elevated recurrence risk.

Career Highlights

Lin’s patent reflects an approach to applying genetic variation in angiogenesis-related genes to prostate cancer risk assessment. The work connects molecular profiling with clinical information to help characterize the possibility of recurrence following surgery.

Collaborations

The supplied information lists Thomas A. Sellers and Jong Park among Lin’s coworkers. It does not specify their roles in the patent or the extent of their collaboration.

Conclusion

Hui-Yi Lin’s recorded patent focuses on using genetic markers to assess prostate cancer recurrence risk, highlighting the potential role of molecular data in supporting clinical evaluation.